Investment to allow Caldan to translate work on free fatty acid receptors initiated in their laboratories
The agreement will enable LifeArc to enhance our antibody drug discovery capabilities
LifeArc’s Seed Fund has invested £1.5 million in Ducentis BioTherapeutics to develop novel drug therapies for inflammatory and autoimmune disease
LifeArc receives US$1.3bn for a portion of royalty interests in Keytruda (pembrolizumab), making us one of the UK’s leading medical research charities by size of investment assets
Three-year partnership to fund clinical application of biomarker strategies to help progress novel drug candidates to clinical evaluation stage
Three-year programme will focus on ion channel drug discovery, to evaluate if small molecule modulators, optimised as part of the research, could show efficacy in treating chronic pain.
London UK, April 16, 2019: LifeArc, one of the UK’s leading medical research charities, has signed a…
New immunotherapy drug targets for cancer will be progressed through a multimillion-pound drug discovery alliance announced today (Wednesday) between Cancer Research UK, LifeArc and Ono Pharmaceutical Co., Ltd.
An experimental medicine to treat the rare inherited skin disorder epidermolysis bullosa (EB) is on track to start trials in patients thanks to the perseverance of the charity team at LifeArc.